Kyverna's long-term data for autoimmune CAR-T Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 24 September, 2026

September 28: Don Ingber of the Wyss Institute joins our Endpoints 11 virtual day for a fireside chat, alongside interviews with the honorees and gala highlights. Open to everyone, free to join. Register now.

presented by Every­body op­ti­mizes the first 20% of pa­tient re­cruit­ment. Tri­als fall apart in the oth­er 80%.

Spotlight In Focus In a changed world for cystic fibrosis, a family's fight reveals a new gap in care

news In another China pact, Lilly makes a deal with InnoCare worth up to $3.35B Kyverna says long-term data bolster FDA submission for rare autoimmune CAR-T FDA adcomm votes in favor of benefit-risk of Grail’s cancer test

Oct 08 11:00 am ET Site-central discordance in oncology trial imaging: New benchmarks and management strategies sponsored by Perceptive Imaging Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.

in case you missed it 1. Baby KJ's gene editing drug cost $1.65M to make, Fyodor Urnov says 2. Updated: Roivant reports Phase 2b lupus failure for an FcRn drug 3. News Briefing Chinese vaccine scandal leads to life sentence; Flagship wins defense contract 4. Enveda raises its third megaround in as many years for I&I and weight maintenance drug candidates